Characterisation of interstitial lung disease (ILD) diagnostic practice around the world and implications on diagnostic agreement and access to licensed therapies

The REG ILD Working Group intend to identify features of ILD MDTs associated with more accurate diagnosis of IPF with a view to improving diagnostic accuracy and patient stratification to optimise treatment outcomes worldwide.
To achieve this ultimate aim, two discrete, sequential research phases are proposed:
• Phase I: A global, standardised, systematic evaluation of the diagnostic process employed by a range of dedicated and non-dedicated ILD centres worldwide.
• Phase II: A global MDT ILD case review and diagnosis study to:
1. Phase IIa: Assess the diagnostic agreement across ILD MDTs
2. Phase IIb: Assess the diagnostic accuracy of ILD MDTs.
Lead Investigators:
• Luca Richeldi, Southampton Respiratory Biomedical Research Unit, University of Southampton, Southampton, UK
• Kevin R. Flaherty, Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA
• Fernando J. Martinez, Department of Medicine, Weill Cornell Medical College, New York, USA
• Simon Walsh, Department of Radiology, King’s College London, King’s Health Partners, King’s College Hospital NHS Foundation Trust, Denmark Hill, London, UK
• Jeffery L. Myers, Medical School, Pathology, University of Michigan, Ann Arbor, MI, USA
Research Team:
Alison Chisholm: Chief Scientific Officer of REG, Cambridge, UK
Status: Proposed Study, Seeking Funding
Support: Biogen, GlaxoSmithKline, Veracyte
Registration:
Documents and Publications
Protocol
Abstracts
Presentations
Final Publications
Additional Material